Locket Genomics and Macrogen Sign Business Agreement on 'Precision Genomic Information Production and Utilization'

Rokit Healthcare subsidiary Rokit Genomics, a single-cell analysis specialist company (CEO Kwon Tae-woo, Gil Yoon-ki), announced on the 22nd that it has signed a business agreement with Macrogen (CEO Kim Chang-hoon) for the production and utilization of precision genomic data.

The signing ceremony was attended by Rokit Genomics CEO Kwon Tae-woo, Project Manager Lee Ye-seung, Macrogen CEO Kim Chang-hoon, Vice President Lee Eung-ryong, Director Joo Ji-hyun, Manager Kim Hyung-seok, and other related personnel.

Founded in 2019, Rokit Genomics is a company that provides services to researchers based on single-cell transcriptome and gene analysis technology. The company's services have been recognized as innovative methods in various life sciences and medical science research fields. In particular, it supports genome analysis services essential for precision medicine and the activation of research by bioinformatics professionals.

Through this agreement, the two companies will establish a mutual cooperation system for ▲ production and provision of precision genomic data ▲ joint research and development in the field of precision medicine genomic information utilization ▲ production and provision of single-cell genomic data ▲ production of precision genomic data in the exosome field.

Through the agreement, Macrogen will produce high-quality genomic data based on its specialized technology. Rokit Genomics plans to utilize this data to provide various customized research services and customer bioinformatics analysis services.

Macrogen CEO Kim Chang-hoon said, “Building medical big data is indispensable for personalized treatment and the realization of precision medicine, and among them, securing high-quality genomic data is crucial. We hope that the high-level data produced by our company will be provided to Rokit Genomics and further accelerate the era of future precision medicine.”

Rokit Genomics CEO Kwon Tae-woo said, “This agreement is significant as it creates synergy through cooperation with Macrogen, a leading global genomic analysis company. Our company will strive to produce stable and up-to-date precision genomic data and provide genome and bioinformatics analysis services to customers in the future.”

Meanwhile, Rokit Genomics is expanding its single-cell genome and transcriptome analysis business area. The company provides services not only using the 10x Genomics platform but also the only BD Rhapsody platform in Korea. In addition, it has been performing numerous national projects and showing a steep annual average sales growth rate of over 50% each year.